References
- Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc 1999; 74: 519–528
- Maurin M, Raoult D. Use of aminoglycosides in treatment of infections due to intracellular bacteria. Antimicrob Agents Chemother 2001; 45: 2977–2986
- Forge A, Schacht J. Aminoglycoside antibiotics. Audiol Neurootol 2000; 5: 3–22
- Rastogi R, Sultana Y, Ali A, Aqil M. Particulate and vesicular drug carriers in the management of tuberculosis. Curr Drug Deliv 2006; 3: 121–128
- Chen H, Langer R. Oral particulate delivery: Status and future trends. Adv Drug Deliv Rev 1998; 34: 339–350
- Ilium L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998; 15: 1326–1331
- Onishi H, Machida Y. Biodegradation and distribution of watersoluble chitosan in mice. Biomaterials 1999; 20: 175–182
- Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomed 2006; 1: 117–128
- Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, et al. N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: Biological properties and immunogenicity in a mouse model. Vaccine 2007; 25: 144–153
- Alonso-Sande M, Cuna M, Remunan-Lopez C, Teijeiro-Osorio D, AIonso-Lebrero JL, Alonso MJ. Formation of new glucomannanchitosan nanoparticles and study of their ability to associate and deliver proteins. Macromolecules 2006; 39: 4152–4158
- Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Contr Rel 2001; 73: 255–267
- Ma Z, Yeoh HH, Lim LY. Formulation pH modulates the interaction of insulin with chitosan nanoparticles. J Pharm Sci 2002; 91: 1396–1404
- Katz SE. Ultraviolet method for determination of streptomycin in feeds. Agri Food Chem 1960; 8: 501–503
- Sampath SS, Robinson DH. Comparison of new and existing spectrophotometric methods for the analysis of tobramycin and other aminoglycosides. J Pharm Sci 1990; 79: 428–431
- Friess W, Schlapp M. Release mechanisms from gentamicin loaded poly(lactic-co-glycolic acid) (PLGA) microparticles. J Pharm Sci 2002; 91: 845–855
- van der Lubben IM, Verhoef JC, van Aelst AC, Borchard G, Junginger HE. Chitosan microparticles for oral vaccination: Preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. Biomaterials 2001; 22: 687–694
- Dubey RR, Parikh RH. Two-stage optimization process for formulation of chitosan microspheres. AAPS PharmSciTech 2003; 5: 1–9
- Baldwin SL, D'Souza C, Roberts AD, Kelly BP, Frank A A, Lui MA, et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun 1998; 66: 2951–2959
- Adams LB, Sinha I, Franzblau SG, Krahenbuhl JL, Mehta RT. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob Agents Chemother 1999; 43: 1638–1643
- Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin N Am 2003; 17: 503–528
- Pandey R, Khuller GK. Nanoparticles-based oral drug delivery systems for an injectable antibiotic-streptomycin. Evaluation in a murine tuberculosis model. Chemotherapy 2007; 53: 437–441
- Barrow EL, Winchester GA, Staas JK, Quenelle DC, Barrow WW. Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis infected macrophages. Antimicrob Agents Chemother 1998; 42: 2682–2689
- Dhillon J, Fielding R, Adler-Moore J, Goodall RL, Mitchison D. The activity of low-clearance liposomal amikacin in experimental murine tuberculosis. J Antimicrob Chemother 2001; 48: 869–876
- Florance AT, Jani PU. Particulate delivery: Challenge of the oral route. Pharmaceutical particulate carriers. Therapeutic application, A Rolland. Marcel Dekker, New York 1993; 65–107